Clinical Oncology News
1,021 FOLLOWERS
Clinical Oncology News is to be an independent source of unbiased, accurate and reliable news combined with in-depth expert analysis about the issues that oncologists and hematologists/oncologists care about most. We strive to be a valuable source for oncologists and hematologists/oncologists in providing the best possible care for their patients.
Clinical Oncology News
3y ago
Agility. Flexibility. A can-do attitude to adapt to the unexpected. These are some attributes community oncology practices have needed to survive during the COVID-19 pandemic ..read more
Clinical Oncology News
3y ago
ESMO 2020 saw the presentation of early results from 2 double-blind, placebo-controlled trials examining adjuvant hormonal therapy for resected very high–risk, hormone receptor–positive breast cancer with cyclin dependent kinase (CDK) 4/6 inhibitors or placebo ..read more
Clinical Oncology News
3y ago
The FDA approved relugolix (Orgovyx, Myovant Sciences), the first oral androgen deprivation therapy for adults with advanced prostate cancer ..read more
Clinical Oncology News
3y ago
New data show that in patients with breast cancer undergoing a lumpectomy or excisional biopsy, nonsteroidal anti-inflammatory drugs and opioids deliver comparable pain control ..read more
Clinical Oncology News
3y ago
The FDA approved osimertinib (Tagrisso, AstraZeneca) for adjuvant therapy after tumor resection in adults with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. ..read more
Clinical Oncology News
3y ago
One would be hard-pressed to find someone who doesn’t long to return to normal, rather than practicing mitigation strategies against COVID-19, so the idea that natural herd immunity should be allowed to develop is gaining traction in some circles. The virus already is widespread; why not just let herd immunity develop and reduce the threat ..read more
Clinical Oncology News
3y ago
Gastroenterologist Brian Dooreck, MD, worked with cancer organizations to develop a text-message–based outreach program to help support patients with newly diagnosed colorectal cancer ..read more
Clinical Oncology News
3y ago
The washout period between the last dose of metronidazole and the first dose of the alkylating agent busulfan can be reduced from seven to three days, according to research from the University of Texas MD Anderson Cancer Center, in Houston ..read more
Clinical Oncology News
3y ago
The FDA approved selinexor (Xpovio, Karyopharm) in combination with bortezomib and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy ..read more
Clinical Oncology News
3y ago
The FDA approved margetuximab-cmkb (Margenza, MacroGenics) in combination with chemotherapy for the treatment of adults with metastatic HER2-positive breast cancer who have received two or more anti-HER2 regimens, at least one of which was for metastatic disease ..read more